Orphazyme Provides Regulatory Update from FDA on Arimoclomol for Niemann-Pick Disease Type C

Copenhagen – June 18, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced it has received a...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news